DOCSLIB.ORG

Περιεχόμενα: I: GENERAL CONCEPTS 1. Human

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Περιεχόμενα: I: GENERAL CONCEPTS 1. Human Περιεχόμενα: I: GENERAL CONCEPTS 1. Human Malformations and Their Genetic Basis CHARLES J. EPSTEIN 2. Principles of Differentiation and Morphogenesis scott f. gilbert and ritva rice 3. Model Organisms in the Study of Development and Disease ethan bier and william mcginnis 4. Human Genomics and Human Development Bob Nussbaum II: Patterns of Development 5. Development of Left-Right Asymmetry Hiroshi Hamada 6. Neural Crest Formation and Craniofacial Development Kurt A. Engleka and Jonathan A. Epstein 7. Development of the Nervous System JOHN L. R. RUBENSTEIN AND LUIS PUELLES 8. Development of the Eye David C. Beebe 9. Development of the Ear Donna M. Fekete 10. Molecular Regulation of Cardiogenesis Deepak Srivastava and Joseph T. C. Shieh 11. Update on the Development of the Vascular System and Its Sporadic Disorders M. Michael Cohen Jr 12. MUSCLE AND SOMITE DEVELOPMENT Douglas Anderson and Alan Rawls 13. The Development of Bone and Cartilage shunichi murakami, haruhiko akiyama, And benoit de crombrugghe 14. LIMB DEVELOPMENT MalteSpielmann and Sigmar Stricker 15. The Sex Determination Pathway PETER J. eLLIS and robert p. erickson 16. Development of the Kidney Kevin T. Bush, Mita M. Shah, Dylan L. Steer, Derina E. Sweeney, and Sanjay K. Nigam 17. DEVELOPMENT OF THE ENDODERMAL DERIVATIVES IN LUNG, LIVER, PANCREAS, AND GUT Ben Z. Stanger, 18. Development of Epidermal Appendages: Teeth and Hair ATSUSHI OHAZAMA AND PAUL T. SHARPE III: Defined Core Developmental Pathways Linked to Cilia Part A: Ciliary Functions: Genesis, Transport, and Reabsorbtion 19. Primary Ciliary Dyskinesia (Kartagener's Syndrome) MICHAL WITT AND ZUZANNA BUKOWY-BIERY??O 20. The Molecular Basis of Joubert Syndrome and Related Disorders Jeong Ho Lee and Joseph G. Gleeson 21. The Bardet-Biedl Syndrome Val C. Sheffield, Qihong Zhang, Elise Heon, Arlene V. Drack, Edwin M. Stone and Rivka Carmi 22. The Molecular basis of Oral-facial-digital type I (OFDI) SYNdrome Brunella Franco 23. Meckel syndrome Amanda Leightner and Peter C. Harris 24. From Hydrolethalus to Acrocallosal syndromes: A spectrum of disorders linked to KIF7 gene. Ferechté Encha-RAZAVI AND Tania ATTIE-BITACH 25. Sensenbrenner syndrome (Cranioectodermal dysplasia, CED)-a genetically heterogeneous ciliopathy Joanna Walczak-Sztulpa AND, Anna Latos-Bielenska PART B: THE SONIC HEDGEHOG SIGNALING PATHWAY 27. The Hedgehog Signaling Network M. MICHAEL COHEN 28. SMITH-LEMLI-OPITZ SYNDROME WEN-HANN TAN AND MIRA B. IRONS 29. SHH AND HOLOPROSENCEPHALY KHOSROW S. HOUSCHYAR, ANDREW A. SMITH, AND JILL A. HELMS 30. IHH AND ACROCAPITOFEMORAL DYSPLASIA AND BRACHYDACTYLY A1 JAN HELLEMANS AND GEERT R. MORTIER 31. PTCH AND THE BASAL CELL NEVUS (GORLIN) SYNDROME ERVIN EPSTEIN JR 32. GLI3 AND THE PALLISTER-HALL AND GREIG CEPHALOPOLYSYNDACTYLY SYNDROMES LESLIE G. BIESECKER 33. SALL1 AND THE TOWNES-BROCKS SYNDROME JÜRGEN KOHLHASE 34. MYCN AND FEINGOLD SYNDROME HANS VAN BOKHOVEN AND HAN G. BRUNNER 35. PREAXIAL POLYDACTYLY TYPE 2 AND ASSOCIATED LIMB DEFECTS ROBERT HILL AND LAURA LETTICE PART C: THE WNT SIGNALING PATHWAY 36. THE WNT SIGNALING PATHWAY BEN CHEYETTE, KIMBERLY MULLIGA 37. AXIN2, TOOTH AGENESIS, AND COLORECTAL CANCER PEKKA NIEMINEN, LAURA LAMMI, AND HEIKKI J. JÄRVINEN 38. WNT3 AND TETRA-AMELIA STEPHAN NIEMANN 39. ROR2 AND BRACHYDACTYLY TYPE B AND RECESSIVE ROBINOW SYNDROME ANDREW O. M. WILKIE 40. CENANI-LENZ SYNDROME BERND WOLLNIK 41. GOLTZ SYNDROME (FOCAL DERMAL HYPOPLASIA) IGNATIA B. VAN DEN VEYVER AND V. REID SUTTON 42. WNT10A AND ODONTO-ONYCHO-DERMAL DYSPLASIA HALA MÉGARBANÉ AND ANDRÉ MÉGARBANÉ 43. AL-AWADI-RAAS-ROTHSCHILD SYNDROME/FUHRMANN SYNDROME GEOFF WOODS 44. AXIN AND CAUDAL DUPLICATION ANOMALY CHRISTINE R. C. ZHANG AND SUYINN CHONG PART D: PLANAR CELL POLARITY (PCP) PATHWAY 45. Role of Planar Cell Polarity Genes VANGL1 and VANGL2 in Neural Tube Formation and Neural Tube Defects Elena Torban, Alexandra Iliescu, and Philippe Gros IV: Other Defined Core Developmental Pathways Part A: The Transforming Growth Factor-B Signaling Pathway 46. An Introduction to TGF-? Family Signaling Jacqueline Nguyen and Tamara Alliston 47. NOG and Proximal Symphalangism (SYM1), Multiple Synostosis (SYN1), Tarsal- Carpal Coalition, and Isolated Stapes Ankylosis Stefan Mundlos 48. NODAL Signaling and Heterotaxy Stephanie M. Ware AND John W. Belmont 49. ENG, ACVRL1, and SMAD4 and Hereditary Hemorrhagic Telangiectasia (Osler- Weber-Rendu Syndrome) SUDHA SRINIVASAN, JONATHAN N. BERG, AND DOUGLAS A. MARCHUK 50. RUNX2 and Cleidocranial Dysplasia LINDSAY BURRAGE, YANGJIN BAE, BRENDAN LEE, AND DOBRAWA NAPIERALA 51. AMH/MIS and Its Receptors: The Persistent Müllerian Duct Syndrome Jean-Yves Picard 52. LE3 and Osteopoikilosis, the Buschke-Ollendorff Syndrome and Melorheostosis Geert R. Mortier 53. TGFBR 1/2 and Loeys-Dietz Syndrome Bart L. Loeys and Harry C. Dietz 54. ZEB2 and Mowat-Wilson Syndrome Meredith Wilson, IRINA GIURGEA, AND David Mowa 55. LTBP4 and Urban-Rifkin-Davis Syndrome Zsolt Urban 56. ACVR1 and Fibrodysplasia Ossificans Progressiva Frederick S. Kaplan, O. W. Towler, and Eileen M. Shore 57. The Role of the Latent TGF-? Binding Protein 3, LTBP3, in Oligodontia and Bone Density Abnormality Muhammad Ayub, Abdul Noor, and John B. Vincent Part B: The Tumor Necrosis Factor Signaling Pathway 58. Signaling by TNF and Related Ligands Pascal Schneider 59. The Ectodysplasin Signaling Pathway in Hypohidrotic Ectodermal Dysplasias Jonathan Zonana and Kenneth Huttner Part C: The Fibroblast Growth Factor Signaling Pathway 60. Molecular and Cellular Biology of FGF Signaling DAVID GIVOL AND VERARAGAVAN P. ESWARAKUMAR 61. FGF Receptor Mutations: Bone Dysplasia, Craniosynostosis, and Other Syndrome Andrew O. M. Wilkie 62. FGF10, FGFR2, and FGFR3 and the Lacrimo-Auriculo-Dental-Digital (LADD) Syndrome Jeff Milunsky 63. TWIST1 and the Saethre-Chotzen Syndrome Ethylin Wang Jabs 64. KAL1, FGFR1, FGF8, PROKR2, PROK2 and Kallmann syndrome Jean-Pierre Hardelin and Catherine Dode 65. TIE2 (TEK) and Venous Malformation NISHA LIMAYE, MELANIE UEBELHOER, Laurence M. Boon, John B. Mulliken, and Miikka Vikkula 66. FLT4 (VEGFR3) and Milroy Disease ROBERT E. FERRELL, DAVID N. FINEGOLD, AND CATHERINE J. BATY 67. Focal Facial Dermal Dysplasias Anne M. Slavotinek, Beom Hee Lee, and Robert J Desnick, Part D: The Glia Cell-derived Neurotrophic Factor Signaling 68. Signaling Pathways of Glial cell-derived Neurotrophic Factor Louis Reichardt 69. RET mutation and function in HSCR, MEN2 and other cancers Sumantra Chatterjee, Zachary E. Stine, Andrew S. McCallion, and Aravinda Chakravarti1 Part E: Introduction to Endothelin-B Receptor and SOX10 Pathways 70. Introduction to Endothelin-B Receptor and SOX10 Pathways MONALEE SAHA AND CHERYL E. GARIEPY 71. EDNRB, EDN3, and SOX10 and the Shah-Waardenburg Syndrome (WS4) Joke B.G.M. Verheij and, Robert M. W. Hofstra Part F: The Notch Signaling Pathway 72. Introduction to Notch Signaling ALISON MIYAMOTO AND GERRY WEINMASTER 73. JAG1 and NOTCH2 and the Alagille Syndrome Nancy B. Spinner, Laura D. Leonard Alexandra M. Falsey, and Ian D. Krantz 74. DLL3, MESP2, LFNG, HES7, TBX6 and Spondylocostal Dysostosis Peter D. Turnpenny, Kenro Kusumi, and Sally Dunwoodie Part G: The P13K-LKB1 Pathway 75. The PI3K-LKB1 Pathway REUBEN J. SHAW AND LEWIS C. CANTLEY 76. PTEN and Cowden and Bannayan-Riley-Ruvalcaba syndromes Pauline Funchain and Charis Eng 77. STK11 (LKB1) and Peutz-Jeghers Syndrome Stylianos E. Antonarakis 78. TSC1 and TSC2 and Tuberous Sclerosis David J. Kwiatkowski Part H: The RAS/ERK/MAPK Pathway 79. The RAS Pathway JEFFREY SWENSEN AND DAVID VISKOCHIL 80. Neurofibromatosis Type 1 David H. Gutmann and Heather Riordan 81. Clinical Features of Noonan Syndrome Marco Tartaglia and Bruce D. Gelb 82. HRAS and Costello Syndrome Yoko Aoki, Yoichi Matsubara 83. The Ras/MAPK Pathway and the Cardio-facio-cutaneous Syndrome Kate Rauen 84. RASA1 and Capillary Malformation- Arteriovenous Malformation Nicole Revencu, Laurence M. Boon, John B. Mulliken, and Miikka Vikkula 85. SPRED1 and Legius syndrome Hilde Brems, Ludwine Messiaen,and Eric Legius Part I: Eph-Eph Signaling 86. Introduction to Eph/ephrin signaling in vertebrate development Audrey K. O'Neill and Jeffrey O. Bush 87. Craniofrontonasal syndrome and EFNB1 mutations Peter Wieacker and Judit Horvath V: Transcription Factors and Chromatin ReguLAtors Part A: The Homeobox Gene Family 88. The Role of Hox and Dlx Gene Clusters in Evolution and Development Frank Ruddle 89. HOXA1 Deficiency Syndrome MAX A. TISCHFIELD, ROBERT P ERICKSON, AND ELIZABETH C. ENGLE 90. HoxA11 and Amegakaryocytic Thrombocytopenia with Radioulnar Synostosis amy e. geddis 91. HOXA13 Hand-foot-genital syndrome (MIM#140000) Guttmacher syndrome (MIM#176305 Jeffrey W. Innis 92. HOXD10 mutations associated with congenital vertical talus and pes cavus claw toe limb abnormalities Antony E. Shrimpton and E. Mark Levinsohn 93. HOXD13 and Synpolydactyly frances r. goodman and peter j. scambler 94. EMX2 and HESX1 and Type I Schizencephaly and Septo-Optic Dysplasia DANIEL KELBERMAN AND MEHUL T. DATTANI 95. PDX1 and Pancreatic Agenesis and Type 2 Diabetes melissa k. thomas and joel f. habener 96. MSX1 and hypodontia, orofacial clefting and the Witkop syndrome MARIE-JOSÉ H. VAN DEN BOOGAARD AND HANS-KRISTIAN PLOOS VAN AMSTEL 97. MSX2 in Craniosynostosis and Defects of Skull Ossification Robert Maxson 98. SHOX and Dyschondrosteosis and Turner Syndrome Jay W. Ellison 99. HLXB9 (MNX1) and Sacral Agenesis and the Currarino Syndrome stephen scherer, guiseppe martucciello, elena belloni, and michele torre 100. Branchio-Oto-Renal (BOR)
Load more

Recommended publications
  • The Genetic Heterogeneity of Brachydactyly Type A1: Identifying the Molecular Pathways
    The genetic heterogeneity of brachydactyly type A1: Identifying the molecular pathways Lemuel Jean Racacho Thesis submitted to the Faculty of Graduate Studies and Postdoctoral Studies in partial fulfillment of the requirements for the Doctorate in Philosophy degree in Biochemistry Specialization in Human and Molecular Genetics Department of Biochemistry, Microbiology and Immunology Faculty of Medicine University of Ottawa © Lemuel Jean Racacho, Ottawa, Canada, 2015 Abstract Brachydactyly type A1 (BDA1) is a rare autosomal dominant trait characterized by the shortening of the middle phalanges of digits 2-5 and of the proximal phalange of digit 1 in both hands and feet. Many of the brachymesophalangies including BDA1 have been associated with genetic perturbations along the BMP-SMAD signaling pathway. The goal of this thesis is to identify the molecular pathways that are associated with the BDA1 phenotype through the genetic assessment of BDA1-affected families. We identified four missense mutations that are clustered with other reported BDA1 mutations in the central region of the N-terminal signaling peptide of IHH. We also identified a missense mutation in GDF5 cosegregating with a semi-dominant form of BDA1. In two families we reported two novel BDA1-associated sequence variants in BMPR1B, the gene which codes for the receptor of GDF5. In 2002, we reported a BDA1 trait linked to chromosome 5p13.3 in a Canadian kindred (BDA1B; MIM %607004) but we did not discover a BDA1-causal variant in any of the protein coding genes within the 2.8 Mb critical region. To provide a higher sensitivity of detection, we performed a targeted enrichment of the BDA1B locus followed by high-throughput sequencing.
    [Show full text]
  • Pushing the Limits of Prenatal Ultrasound: a Case of Dorsal Dermal Sinus Associated with an Overt Arnold–Chiari Malformation and a 3Q Duplication
    reproductive medicine Case Report Pushing the Limits of Prenatal Ultrasound: A Case of Dorsal Dermal Sinus Associated with an Overt Arnold–Chiari Malformation and a 3q Duplication Olivier Leroij 1, Lennart Van der Veeken 2,*, Bettina Blaumeiser 3 and Katrien Janssens 3 1 Faculty of Medicine, University of Antwerp, 2610 Wilrijk, Belgium; [email protected] 2 Department of Obstetrics and Gynaecology, University Hospital Antwerp, 2650 Edegem, Belgium 3 Department of Medical Genetics, University Hospital and University of Antwerp, 2650 Edegem, Belgium; [email protected] (B.B.); [email protected] (K.J.) * Correspondence: [email protected] Abstract: We present a case of a fetus with cranial abnormalities typical of open spina bifida but with an intact spine shown on both ultrasound and fetal MRI. Expert ultrasound examination revealed a very small tract between the spine and the skin, and a postmortem examination confirmed the diagnosis of a dorsal dermal sinus. Genetic analysis found a mosaic 3q23q27 duplication in the form of a marker chromosome. This case emphasizes that meticulous prenatal ultrasound examination has the potential to diagnose even closed subtypes of neural tube defects. Furthermore, with cerebral anomalies suggesting a spina bifida, other imaging techniques together with genetic tests and measurement of alpha-fetoprotein in the amniotic fluid should be performed. Citation: Leroij, O.; Van der Veeken, Keywords: dorsal dermal sinus; Arnold–Chiari anomaly; 3q23q27 duplication; mosaic; marker chro- L.; Blaumeiser, B.; Janssens, K. mosome Pushing the Limits of Prenatal Ultrasound: A Case of Dorsal Dermal Sinus Associated with an Overt Arnold–Chiari Malformation and a 3q 1.
    [Show full text]
  • Prevalence and Incidence of Rare Diseases: Bibliographic Data
    Number 1 | January 2019 Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order) www.orpha.net www.orphadata.org If a range of national data is available, the average is Methodology calculated to estimate the worldwide or European prevalence or incidence. When a range of data sources is available, the most Orphanet carries out a systematic survey of literature in recent data source that meets a certain number of quality order to estimate the prevalence and incidence of rare criteria is favoured (registries, meta-analyses, diseases. This study aims to collect new data regarding population-based studies, large cohorts studies). point prevalence, birth prevalence and incidence, and to update already published data according to new For congenital diseases, the prevalence is estimated, so scientific studies or other available data. that: Prevalence = birth prevalence x (patient life This data is presented in the following reports published expectancy/general population life expectancy). biannually: When only incidence data is documented, the prevalence is estimated when possible, so that : • Prevalence, incidence or number of published cases listed by diseases (in alphabetical order); Prevalence = incidence x disease mean duration. • Diseases listed by decreasing prevalence, incidence When neither prevalence nor incidence data is available, or number of published cases; which is the case for very rare diseases, the number of cases or families documented in the medical literature is Data collection provided. A number of different sources are used : Limitations of the study • Registries (RARECARE, EUROCAT, etc) ; The prevalence and incidence data presented in this report are only estimations and cannot be considered to • National/international health institutes and agencies be absolutely correct.
    [Show full text]
  • Orphanet Report Series Rare Diseases Collection
    Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic
    [Show full text]
  • Spectrum of Mutations and Genotype ± Phenotype Analysis in Currarino Syndrome
    European Journal of Human Genetics (2001) 9, 599 ± 605 ã 2001 Nature Publishing Group All rights reserved 1018-4813/01 $15.00 www.nature.com/ejhg ARTICLE Spectrum of mutations and genotype ± phenotype analysis in Currarino syndrome Joachim KoÈchling1, Mohsen Karbasiyan2 and Andre Reis*,2,3 1Department of Pediatric Oncology/Hematology, ChariteÂ, Humboldt University, Berlin, Germany; 2Institute of Human Genetics, ChariteÂ, Humboldt University, Berlin, Germany; 3Institute of Human Genetics, Friedrich- Alexander University Erlangen-NuÈrnberg, Erlangen, Germany The triad of a presacral tumour, sacral agenesis and anorectal malformation constitutes the Currarino syndrome which is caused by dorsal-ventral patterning defects during embryonic development. The syndrome occurs in the majority of patients as an autosomal dominant trait associated with mutations in the homeobox gene HLXB9 which encodes the nuclear protein HB9. However, genotype ± phenotype analyses have been performed only in a few families and there are no reports about the specific impact of HLXB9 mutations on HB9 function. We performed a mutational analysis in 72 individuals from nine families with Currarino syndrome. We identified a total of five HLXB9 mutations, four novel and one known mutation, in four out of four families and one out of five sporadic cases. Highly variable phenotypes and a low penetrance with half of all carriers being clinically asymptomatic were found in three families, whereas affected members of one family showed almost identical phenotypes. However, an obvious genotype ± phenotype correlation was not found. While HLXB9 mutations were diagnosed in 23 patients, no mutation or microdeletion was detected in four sporadic patients with Currarino syndrome. The distribution pattern of here and previously reported HLXB9 mutations indicates mutational predilection sites within exon 1 and the homeobox.
    [Show full text]
  • Test Catalogue August 2019
    Test Catalogue August 2019 www.centogene.com/catalogue Table of Contents CENTOGENE CLINICAL DIAGNOSTIC PRODUCTS AND SERVICES › Whole Exome Testing 4 › Whole Genome Testing 5 › Genome wide CNV Analysis 5 › Somatic Mutation Analyses 5 › Biomarker Testing, Biochemical Testing 6 › Prenatal Testing 7 › Additional Services 7 › Metabolic Diseases 9 - 21 › Neurological Diseases 23 - 47 › Ophthalmological Diseases 49 - 55 › Ear, Nose and Throat Diseases 57 - 61 › Bone, Skin and Immune Diseases 63 - 73 › Cardiological Diseases 75 - 79 › Vascular Diseases 81 - 82 › Liver, Kidney and Endocrinological Diseases 83 - 89 › Reproductive Genetics 91 › Haematological Diseases 93 - 96 › Malformation and/or Retardation Syndromes 97 - 107 › Oncogenetics 109 - 113 ® › CentoXome - Sequencing targeting exonic regions of ~20.000 genes Test Test name Description code CentoXome® Solo Medical interpretation/report of WES findings for index 50029 CentoXome® Solo - Variants Raw data; fastQ, BAM, Vcf files along with variant annotated file in xls format for index 50028 CentoXome® Solo - with CNV Medical interpretation/report of WES including CNV findings for index 50103 Medical interpretation/report of WES in index, package including genome wide analyses of structural/ CentoXome® Solo - with sWGS 50104 large CNVs through sWGS Medical interpretation/report of WES in index, package including genome wide analyses of structural/ CentoXome® Solo - with aCGH 750k 50122 large CNVs through 750k microarray Medical interpretation/report of WES in index, package including genome
    [Show full text]
  • Mutation Analysis and Embryonic Expression of the HLXB9 Currarino Syndrome Gene D
    Am. J. Hum. Genet. 66:1504±1515, 2000 Mutation Analysis and Embryonic Expression of the HLXB9 Currarino Syndrome Gene D. M. Hagan,1,* A. J. Ross,1,* T. Strachan,1 S. A. Lynch,1 V. Ruiz-Perez,1 Y. M. Wang,1 P. Scambler,2 E. Custard,2 W. Reardon,3 S. Hassan,2 M. Muenke,8 P. Nixon,2 C. Papapetrou,2 R. M. Winter,3 Y. Edwards,4 K. Morrison,4 M. Barrow,9 M. P. Cordier-Alex,10 P. Correia,11 P. A. Galvin-Parton,12 S. Gaskill,13 K. J. Gaskin,14 S. Garcia-Minaur,15 R. Gereige,16 R. Hayward,5 T. Homfray,7 C. McKeown,17 V. Murday,7 H. Plauchu,10 N. Shannon,18 L. Spitz,6 and S. Lindsay1 1Human Genetics Unit, School of Biochemistry and Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne; 2Molecular Medicine Unit and 3Department of Clinical Genetics and Fetal Medicine, Institute of Child Health, 4MRC Human Biochemical Genetics Unit, University College, 5Department of Neurosurgery and 6Nuf®eld Department of Surgery, Great Ormond Street Hospital for Children, and 7Department of Medical Genetics, St. Georges Hospital Medical School, London; 8Medical Genetics Branch, National Human Genome Research Institute, Bethesda; 9Department of Clinical Genetics, Leicester Royal In®rmary, Leicester; 10Hopital Hotel Dieu, Lyon; 11IFF-Fiocruz, Rio de Janeiro; 12Department of Pediatrics, State University of New York at Stony Brook, Stony Brook; 13Medical Drive, San Antonio; 14Royal Alexandra Hospital for Sick Children, Camperdown, New South Wales, Australia; 15Clinica Materno-Infantil, Hospital de Cruces, Barakaldo, Spain; 16All Children's Hospital, St. Petersburg, FL; 17Clinical Genetics Unit, Birmingham Women's Hospital, Birmingham, United Kingdom; and 18Centre for Human Genetics, Shef®eld The HLXB9 homeobox gene was recently identi®ed as a locus for autosomal dominant Currarino syndrome, also known as hereditary sacral agenesis (HSA).
    [Show full text]
  • 2 Genetics of Anorectal Malformations
    17 2 Genetics of Anorectal Malformations Giuseppe Martucciello Contents blastogenesis often involve two or more progenitor fields. This fact may explain the cause of subgroups 2.1 Introduction . 17 of ARM that form part of complex phenotypes due 2.2 Non-syndromic ARM . 17 to developmental field defects. These complex phe- 2.3 ARM Associated with Other Systemic notypes are considered as end results of pleiotropic Malformations . 18 effects of single causal events that might be chromo- 2.4 Aetiological Classification . 20 somal, monogenic or even teratogenic [72]. 2.4.1 Chromosomal Anomalies Classifying ARM from the genetic point of view is Associated with ARM . 20 2.4.2 Down Syndrome . 20 not easy since they present different forms that are be- 2.4.3 Cat-Eye Syndrome . 20 lieved to be influenced by different factors such as sex 2.4.4 Genetic Syndromes Associated and associated anomalies. ARM can be the only path- with ARM . 21 ological finding (non-syndromic) or as part of a more 2.4.4.1 Townes-Brocks Syndrome . 21 complex phenotype (syndromic), and may occur in a 2.4.4.2 FG Syndrome . 21 single affected individual (sporadic) or in more than 2.4.4.3 Pallister-Hall Syndrome . 21 one individual in the same family (familial) with dif- 2.4.4.4 VACTERL Association (VATER) . 22 ferent modes of inheritance. There are gender differ- 2.4.4.5 Sirenomelia . 22 ences, with remarkably higher preponderance in boys 2.4.4.6 Caudal Regression Syndrome . 23 for more complex ARM forms, while the less severe 2.4.4.7 Currarino Syndrome .
    [Show full text]
  • Chromosomal Microarray, Postnatal, Clarisure® Oligo-SNP
    Diagnostic Services Pediatrics Test Summary Chromosomal Microarray, Postnatal, ClariSure® Oligo-SNP The American College of Medical Genetics (ACMG) Test Code: 16478(X) recommends CMA testing as a first-line genetic test for developmental delay, intellectual disability, ASDs, and Specimen Requirements: 10 mL room-temperature whole multiple congenital anomalies.2,4 This recommendation blood (sodium-heparin, green-top tube); 5 mL minimum is based, in part, on a literature review that included over 21,000 patients with developmental delay/intellectual CPT Code*: 81229 disability, ASDs, or multiple congenital anomalies. The diagnostic yield was 15% to 20% for CMA testing versus ~3% for G-banded karyotyping and ~6% for subtelomeric Clinical Use fluorescence in situ hybridization (FISH) in combination • Determine the genetic etiology of developmental with G-banded karyotyping.5 In individuals with complex delay, intellectual disability, autism spectrum disorders ASDs, CMA testing can result in a diagnostic yield of over (ASDs; pervasive developmental disorders), and 25%.2 ACMG still considers karyotyping a first-line test multiple congenital anomalies when patients are suspected of having a recognizable • Confirm or exclude the diagnosis of known chromosomal syndrome such as trisomy 21 or 18, Turner chromosomal syndromes syndrome, or Klinefelter syndrome.2,4 • Further define ambiguities arising from cytogenetic The oligonucleotide-single nucleotide polymorphism or FISH studies (oligo-SNP) array contains over 2.6 million probes and • Assist in clinical management and genetic counseling covers regions of known and likely CNVs. It can confirm the diagnosis of suspected disorders associated with known Clinical Background chromosomal syndromes and is especially well suited Global developmental delay, intellectual disability (mental for determining the genetic cause of less well-described retardation), ASDs, and multiple congenital anomalies may disorders.
    [Show full text]
  • ISCA Disease List
    Gene content of ISCA arrays 402 gene regions, 377 registered OMIM records syndrome chromosome Gene Band OMIM ISCA 8x60k 1p36 deletion chr1 SKI 1p36 164780 yes 1p36 deletion chr1 TP73 1p36 601990 yes Bartter 4 chr1 CLCNKA 1p36 602024 yes Bartter 3 chr1 CLCNKB 1p36 602023 yes Bartter 4 chr1 BSND 1p32 606412 yes NFIA Haploinsufficiency chr1 NFIA 1p31 600727 yes monosomy 1p31 p22 chr1 DIRAS3 1p31 605193 yes Stickler syndrome chr1 COL11A1 1p21 120280 yes atrial fibrillation chr1 GJA5 1q21 121013 yes Thrombocytopenia absent radius syndrome chr1 GJA8 1q21 600897 yes Short stature chr1 LHX4 1q25 602146 yes Van der Woude syndrome chr1 IRF6 1q32 607199 yes Fryns 1q41 chr1 DISP1 1q41 607502 yes autism chr1 DISC1 1q42 605210 yes MR chr1 TBCE 1q42 604934 yes Feingold chr2 MYCN 2q24 164840 yes Pseudovaginal perineoscrotal hypospadias chr2 SRD5A2 2p23 607306 yes Noonan 4 chr2 SOS1 2p22 182530 yes Cystinuria with mitochondrial disease chr2 SLC3A1 2p21 104614 yes Cystinuria with mitochondrial disease chr2 PREPL 2p21 104614 yes Holopresencaphly 2 chr2 SIX3 2p21 603714 yes autism chr2 NRXN1 2p16 600565 yes MicrodeletionReg 2p15p16.1 microdeletion chr2 2p15 602559 yes ion Nephronophthsis 1 chr2 NPHP1 2q13 607100 yes Holoprosencephaly 9 chr2 GLI2 2q14 165230 yes visceral heterotaxy chr2 CFC1 2q21 605194 yes Mowat-Wilson syndrome chr2 ZEB2 2q22 605802 yes autism chr2 SLC4A10 2q24 605556 yes SCN1A-related seizures chr2 SCN1A 2q24 182389 yes HYPOMYELINATION, GLOBAL CEREBRAL chr2 SLC25A12 2q31 603667 yes Split/hand foot malformation -5 chr2 DLX1 2q31 600029 yes
    [Show full text]
  • Prenatal Microarray Disorders List V19.1
    Prenatal Microarray Disorders List v19.1 This "whole genome" array may identify genetic conditions not included in this list. If there is a family history of a known suspected genetic condition unrelated to the reason for testing, please contact the laboratory to discuss prior to sample submission. Chromosome Disorder / Syndrome OMIM Candidate Gene(s) Position 1p36 deletion syndrome 607872 1p36 Multiple 1q21.1 deletion syndrome, 1.35 Mb 612474 1q21.1-q21.2 Multiple 1q21.1 deletion with susceptibility to TAR 274000 1q21.1-q21.2 Multiple 1q21.1 duplication syndrome 612475 1q21.1-q21.2 Multiple 1q41-q42 deletion syndrome 612530 1q41-q42.12 Multiple 1q43-q44 deletion syndrome 612337 1q43-q44 AKT3, ZBTB18 2p16.1-p15 deletion syndrome 612513 2p16.1-p15 Multiple 2p21 microdeletion, homozygous 606407 2p21 Multiple 2q23.1 deletion syndrome 156200 2q23.1 MBD5 2q32-q33 deletion syndrome/ 2q33.1 deletion syndrome 612313 2q32-q33 SATB2 2q37 deletion syndrome 600430 2q37.3 HDAC4 3q13.31 deletion syndrome 615433 3q13.31 ZBTB20 3q26.33-3q27.2 deletion syndrome -- 3q26.33-3q27.2 Multiple 3q27.3 deletion syndrome -- 3q27.3 Multiple 3q29 deletion syndrome 609425 3q29 Multiple 4q21 deletion syndrome 613509 4q21 Multiple 5q14.3 deletion syndrome 613443 5q14.3 MEF2C 6pter-p24 deletion syndrome 612582 6pter-p24 Multiple 7q11.23 distal deletion syndrome 613729 7q11.23 Multiple 7q11.23 duplication syndrome 609757 7q11.23 Multiple 8p23.1 deletion/duplication syndrome 600576 8p23.1 GATA4 9q22.3 deletion syndrome 601309 9q22.3 PTCH1, FANCC 9q34.3 deletion syndrome
    [Show full text]
  • Utviklingsavvik V02
    2/1/2021 Utviklingsavvik v02 Avdeling for medisinsk genetikk Utviklingsavvik Genpanel, versjon v02 * Enkelte genomiske regioner har lav eller ingen sekvensdekning ved eksomsekvensering. Dette skyldes at de har stor likhet med andre områder i genomet, slik at spesifikk gjenkjennelse av disse områdene og påvisning av varianter i disse områdene, blir vanskelig og upålitelig. Disse genetiske regionene har vi identifisert ved å benytte USCS segmental duplication hvor områder større enn 1 kb og ≥90% likhet med andre regioner i genomet, gjenkjennes (https://genome.ucsc.edu). For noen gener ligger alle ekson i områder med segmentale duplikasjoner: ACTB, ACTG1, ASNS, ATAD3A, CA5A, CFC1, CLCNKB, CYCS, DDX11, GBA, GJA1, MSTO1, PIGC, RBM8A, RPL15, SBDS, SDHA, SHOX, SLC6A8 Vi gjør oppmerksom på at ved identifiseringav ekson oppstrøms for startkodon kan eksonnummereringen endres uten at transkript ID endres. Avdelingens websider har en full oversikt over områder som er affisert av segmentale duplikasjoner. ** Transkriptets kodende ekson. Ekson Gen Gen affisert (HGNC (HGNC Transkript Ekson** Fenotype av symbol) ID) segdup* AAAS 13666 NM_015665.6 1-16 Achalasia-addisonianism-alacrimia syndrome, 231550 AARS 20 NM_001605.2 2-21 Epileptic encephalopathy, early infantile, 29 616339 AARS2 21022 NM_020745.4 1-22 Combined oxidative phosphorylation deficiency 8, 614096 AASS 17366 NM_005763.4 2-24 Hyperlysinaemia (Disorders of histidine, tryptophan or lysine metabolism) ABAT 23 NM_020686.6 2-16 GABA transaminase deficiency (Disorders of neurotransmitter metabolism, gamma-aminobutyrate)
    [Show full text]